Education
About Us
Working with TipRanks
Follow Us
RaQualia Pharma Inc. (JP:4579)
:4579
4579 Stock Chart & Stats
¥1010.00
-¥6.00(-1.49%)
At close: 4:00 PM EST
¥1010.00
-¥6.00(-1.49%)
Day’s Range― - ―
52-Week Range¥301.00 - ¥1,465.00
Previous CloseN/A
Volume117.60K
Average Volume (3M)352.93K
Market Cap
¥26.05B
Enterprise Value¥25.55B
Total Cash (Recent Filing)¥3.54B
Total Debt (Recent Filing)¥3.05B
Price to Earnings (P/E)92.1
Beta0.83
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)35.82
Shares Outstanding24,458,673
10 Day Avg. Volume795,170
30 Day Avg. Volume352,926
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.49
Price to Sales (P/S)2.67
P/FCF Ratio98.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing-driven Business ModelA licensing and collaboration model lets RaQualia monetize R&D without bearing full late‑stage development and commercialization costs. That durable structure can provide non-dilutive upfronts, milestone and royalty streams, reduce funding needs, and align incentives with larger partners over multi-year programs.
Moderate Leverage And Equity BaseA debt-to-equity around 0.51 and a relatively healthy equity ratio indicate balanced capitalization. This creates financial flexibility to fund near-term R&D or partnerships, allows access to debt without extreme strain, and supports multiyear development programs without immediate solvency pressure.
Gross Margin StrengthA strong gross profit margin signals favorable product or program economics and cost structure at the direct production level. If RaQualia can grow partnered or retained product sales, this gross-margin base supports long-term operating leverage and potential profitability once operating expenses are controlled.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow and negative FCF-to-income show the company struggles to convert activities into cash. Over months this raises funding risk for ongoing trials, forces reliance on partners or capital markets, and constrains independent advancement of higher‑cost clinical programs.
Declining Revenue And Operating LossesA decline in trailing revenue combined with negative EBIT and net margins points to structural commercial or pipeline monetization challenges. Sustained revenue contraction and losses limit reinvestment capacity, weaken bargaining power in partnerships, and may necessitate recurring external financing.
High Development And Clinical-stage RiskA business centered on preclinical and clinical R&D carries long timelines, binary trial outcomes, and high cash burn. Success depends on positive clinical readouts or partner deals; failures or delays can materially impair value and require new financing, making performance sensitive to program outcomes over months.
RaQualia Pharma Inc. News
4579 FAQ
What was RaQualia Pharma Inc.’s price range in the past 12 months?
RaQualia Pharma Inc. lowest stock price was ¥301.00 and its highest was ¥1465.00 in the past 12 months.
What is RaQualia Pharma Inc.’s market cap?
RaQualia Pharma Inc.’s market cap is ¥26.05B.
When is RaQualia Pharma Inc.’s upcoming earnings report date?
RaQualia Pharma Inc.’s upcoming earnings report date is May 20, 2026 which is in 93 days.
How were RaQualia Pharma Inc.’s earnings last quarter?
RaQualia Pharma Inc. released its earnings results on Feb 13, 2026. The company reported ¥35.82 earnings per share for the quarter, beating the consensus estimate of N/A by ¥35.82.
Is RaQualia Pharma Inc. overvalued?
According to Wall Street analysts RaQualia Pharma Inc.’s price is currently Overvalued.
Does RaQualia Pharma Inc. pay dividends?
RaQualia Pharma Inc. does not currently pay dividends.
What is RaQualia Pharma Inc.’s EPS estimate?
RaQualia Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RaQualia Pharma Inc. have?
RaQualia Pharma Inc. has 24,458,673 shares outstanding.
What happened to RaQualia Pharma Inc.’s price movement after its last earnings report?
RaQualia Pharma Inc. reported an EPS of ¥35.82 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.207%.
Which hedge fund is a major shareholder of RaQualia Pharma Inc.?
Currently, no hedge funds are holding shares in JP:4579
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaQualia Pharma Inc.
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
Technical Analysis
Oncolys BioPharma, Inc.
―
StemRIM Inc.
―
CellSource Co., Ltd.
―
STELLA PHARMA CORPORATION
―
ReproCELL Inc.
―